TITLE

Spotlight on Bupropion in Major Depressive Disorder

AUTHOR(S)
Dhillon, Sohita; Yang, Lily P H; Curran, Monique P
PUB. DATE
May 2008
SOURCE
CNS Drugs;2008, Vol. 22 Issue 7, p613
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Bupropion is presumed to be a dopamine-noradrenaline (norepinephrine) reuptake inhibitor and is an effective antidepressant. It is available as three oral formulations: (i) bupropion immediate release (IR) [Wellbutrin] administered three times daily; (ii) bupropion sustained release (SR) [Wellbutrin SR] administered twice daily; and (iii) bupropion extended/modified release (XR) [Wellbutrin XL/Wellbutrin XR] administered once daily. All three formulations are bioequivalent in terms of systemic exposure to bupropion. Oral three-times-daily bupropion IR was effective and generally well tolerated in the treatment of major depressive disorder (MDD). It was as efficacious and as well tolerated as some TCAs and the SSRI fluoxetine. Moreover, it was associated with less somnolence and weight gain than some TCAs. Twice-daily bupropion SR was also efficacious and generally well tolerated in the treatment of MDD. It was as effective as and had a generally similar tolerability profile to some SSRIs, but had the advantage of less somnolence and sexual dysfunction. The efficacy of bupropion XR in terms of primary efficacy measures was established in two of six well designed placebo-controlled studies. Bupropion XR also demonstrated efficacy in terms of some secondary outcomes in five of these studies. Additionally, bupropion XR was similar, in terms of the primary efficacy outcomes, to the SSRI escitalopram in two placebo-controlled trials and to the serotonin-noradrenaline reuptake inhibitor (SNRI) venlafaxine extended release (XR) in two trials (one of which was placebo-controlled), but not in a third placebo-controlled trial where venlafaxine XR was better than bupropion XR. It was generally as well tolerated as escitalopram and venlafaxine XR, but was associated with less sexual dysfunction than escitalopram. Available clinical data suggest that bupropion is an effective and generally well tolerated option in the treatment of MDD, with the newer formulations having the advantage of reduced frequency of daily administration.
ACCESSION #
32686419

 

Related Articles

  • Estimates of Serotonin and Norepinephrine Transporter Inhibition in Depressed Patients Treated with Paroxetine or Venlafaxine. Owens, Michael J.; Krulewicz, Stan; Simon, Jeffrey S.; Sheehan, David V.; Thase, Michael E.; Carpenter, David J.; Plott, Susan J.; Nemeroff, Charles B. // Neuropsychopharmacology;Dec2008, Vol. 33 Issue 13, p3201 

    Paroxetine and venlafaxine are potent serotonin transporter (SERT) antagonists and weaker norepinephrine transporter (NET) antagonists. However, the relative magnitude of effect at each of these sites during treatment is unknown. Using a novel blood assay that estimates CNS transporter occupancy...

  • Intermittent and continuous swim stress-induced behavioral depression: sensitivity to norepinephrine- and serotonin-selective antidepressants. Drugan, Robert C.; Macomber, Heather; Warner, Timothy // Psychopharmacology;Oct2010, Vol. 212 Issue 1, p85 

    Intermittent swim stress (ISS) produces deficits in swim escape learning and increases immobility in the forced swim test (FST). A previous attempt to reverse this immobility with the selective serotonin reuptake inhibitor (SSRI), fluoxetine (FLX), was unsuccessful, but the sensitivity of this...

  • Escitalopram: A Pharmacoeconomic Review of its Use in Depression. Croom, Katherine F.; Plosker, Greg L. // PharmacoEconomics;2003, Vol. 21 Issue 16, p1185 

    Escitalopram (Cipralex[sup ®]), a new highly selective serotonin reuptake inhibitor (SSRI), is the active S-enantiomer of RS-citalopram. It is effective in the treatment of patients with major depressive disorder (MDD) and may have a faster onset of therapeutic effect than citalopram. It has...

  • Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Thase, Michael E.; Entsuah, A. Richard; Rudolph, Richard L.; Thase, M E; Entsuah, A R; Rudolph, R L // British Journal of Psychiatry;Mar2001, Vol. 178, p234 

    Background: It had been suggested that the antidepressant venlafaxine, which inhibits reuptake of both serotonin and (at higher doses) noradrenaline, may result in better outcomes than treatment with selective serotonin reuptake inhibitors (SSRIs).Aims: To compare...

  • ACP treatment guideline for antidepressants. Elliott, William T. // Clinical Cardiology Alert;Jan2009 Pharmacology, p2 

    The article deals with the practice guideline issued by the American College of Physicians in January 2009 concerning the use of antidepressants to treat depressive disorders. Particular focus is given on second-generation antidepressants like selective serotonin reuptake inhibitors (SSRI)...

  • A drug utilisation study of antidepressants in children and adolescents using the General Practice Research Database. Murray, M. L.; de Vries, C. S.; Wong, I. C. K. // Archives of Disease in Childhood;Dec2004, Vol. 89 Issue 12, p1098 

    Aims: To characterise prescribing patterns of antidepressants (ATDs) to children and adolescents aged 18 years in the UK. Methods: Subjects issued at least one AID prescription between 1 January 1992 and 31 December 2001 were identified from the UK General Practice Research Database. Prescribing...

  • INFLUENCE OF SEROTONIN TRANSPORTER-LINKED POLYMORPHIC REGION (5-HTTLPR) VARAINTS ON CLINICAL OUTCOMES IN THAI PATIENTS WITH DEPRESSIVE DISORDER. Kamolwan Tantipiwattanaskul; Duangchit Panomvana; Verayuth Praphanphoj // International Journal of Pharmacy;2013, Vol. 3 Issue 3, p426 

    The influence of the serotonin transporter polymorphisms on fluoxetine clinical outcomes was determined in 69 Thai patients with major depressive disorder. The results indicated that patients with l/l genotype had a significantly better response to fluoxetine treatment when compared with s...

  • Psychopharmacology for the Clinician. Blier, Pierre // Journal of Psychiatry & Neuroscience;Jul2006, Vol. 31 Issue 4, p288 

    The article presents a case study of treating depression with selective norepinephrine reuptake inhibitors to a 55-year-old patient. Upon referral, his symptoms were of moderate intensity, and he was not taking any antidepressants. No one doubts that the antidepressants desipramine,...

  • Combined catecholamine and indoleamine depletion following response to ECT. Cassidy, Frederick; Weiner, Richard D.; Cooper, Thomas B.; Carroll, Bernard J. // British Journal of Psychiatry;Jun2010, Vol. 196 Issue 6, p493 

    The mechanism of action of electroconvulsive therapy (ECT) in treating major depression is unknown. We studied two candidate mechanisms through inhibiting simultaneously the synthesis of noradrenaline and serotonin in patients immediately after successful treatment with ECT using a randomised,...

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics